User:Mr. Ibrahem/Necitumumab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Trade names | Portrazza |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous infusion |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~14 days |
| Chemical and physical data | |
| Formula | C6436H9958N1702O2020S42 |
| Molar mass | 144844.87 g·mol−1 |
  (what is this?) (verify) | |
Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC).[1] Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread.[1] Such use; however, is not recommended in the United Kingdom.[3] It is given by gradual injection into a vein.[2]
Common side effects include rash and low magnesium.[2] Other side effects may include cardiac arrest and blood clots.[2] Use in pregnancy may harm the baby.[2] It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).[3]
Necitumumab was approved for medical use in the United States in 2015.[1] While it was approved for use in Europe in 2016, this approval was subsequently withdrawn.[4] In the United Kingdom it cost the NHS £1,450 per dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[5]
References[edit]
- ^ a b c d "Necitumumab Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 November 2021.
- ^ a b c d e f "DailyMed - PORTRAZZA- necitumumab solution". dailymed.nlm.nih.gov. Archived from the original on 9 August 2021. Retrieved 12 November 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
- ^ "Portrazza". Archived from the original on 7 August 2021. Retrieved 12 November 2021.
- ^ "Portrazza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 12 November 2021.